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Abstract
Genostem (acronym for Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side )“ ”
has been an European consortium of 30 teams working together on human bone marrow Mesenchymal Stem Cell (MSC) biological
properties and repair capacity. Part of Genostem activity has been dedicated to the study of basic issues on undifferentiated MSCs
properties and on signalling pathways leading to the differentiation into 3 of the connective tissue lineages, osteoblastic, chondrocytic
and tenocytic. We have evidenced that native bone marrow MSCs and stromal cells, forming the niche of hematopoietic stem cells,
were the same cellular entity located abluminally from marrow sinus endothelial cells. We have also shown that culture-amplified,
clonogenic and highly-proliferative MSCs were bona fide stem cells, sharing with other stem cell types the major attributes of
self-renewal and of multipotential priming to the lineages to which they can differentiate (osteoblasts, chondrocytes, adipocytes and
vascular smooth muscle cells/pericytes). Extensive transcription profiling and and assays were applied to identifyin vitro in vivo 
genes involved in differentiation. Thus we have described novel factors implicated in osteogenesis ( ),FHL2, ITGA5, Fgf18 
chondrogenesis ( ) and tenogenesis ( ). Another part of Genostem activity has been devoted to studies of the repairFOXO1A Smad8 
capacity of MSCs in animal models, a prerequisite for future clinical trials. We have developed novel scaffolds (chitosan,
pharmacologically active microcarriers) useful for the repair of both bone and cartilage. Finally and most importantly, we have
shown that locally implanted MSCs effectively repair bone, cartilage and tendon.
MESH Keywords Animals ; Bone Marrow Cells ; cytology ; Cell Culture Techniques ; standards ; Cell Differentiation ; Cell Proliferation ; Humans ; Mesenchymal Stem
Cells ; cytology ; Tissue Engineering
Author Keywords differentiation ; stem cell ; bone ; cartilage ; tendon ; smooth muscle ; regenerative medicine
Genostem, acronym for Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side“ ”
has been an European Integrated Project sponsored for 4 years by the European Community. It has included 30 teams, belonging to
different European countries and to Israel, working together from the beginning of 2004 to the end of 2007.
This review highlights the essential scientific data provided by the consortium.
CELLULAR AND MOLECULAR ASPECTS
Approximately half of Genostem activity has been dedicated to the study of basic issues concerning bone marrow MSCs, the
properties of undifferentiated MSCs and the signalling pathways leading to the differentiation into 3 of the connective tissue lineages,
osteoblastic, chondrocytic and tenocytic.
Proliferating human bone marrow MSCs
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Contrary to bone marrow native cells, that remain quiescent in vivo, MSCs actively proliferate once seeded in appropriate medium.
Many attributes of the proliferating cells remain controversial to the point that the cell denomination varies from one author to the other
(mesenchymal stem, or progenitor, or stromal cells, skeletal stem cells, stromal stem cells .). In Genostem, we have retained the term…
Mesenchymal Stem Cells for the population of human bone marrow cells culture amplified in standardized conditions and whose attributes
are described below.
Standardization of the culture system
Standardisation of the culture system for ex vivo amplification was a pre-requisite to our work so that results could be compared
between labs. Standards for the culture system included the use of alpha-MEM without nucleotides and of fetal calf serum selected for cell
growth, and a cell seeding concentration of 5 10 cells/cm at culture initiation and of 10 /cm at each passage ( ). Fibroblast growth× 4 2 3 2 1 
factor-2 (FGF-2) increased the growth of MSCs in elderly patients (> 60 years old), but not in children or younger adults ( ). FGF-2 was2 
therefore added at low concentration (1 ng/mL twice a week at medium renewal) in culture of elderly patients.
Proliferation potential
How primary layers are generated, to which extent do cells proliferate and which factors are implicated in MSC proliferation remained
largely unknown and controversial. Studies in Genostem have addressed these issues.
Using large-scale Taqman Low-Density Array based on qRT-PCR, we have compared the expression level of 300 transcripts in
passage 1 primary layers and in fast-growing clones developed at culture initiation and grown for a similar amount of time than primary
layers. Gene expression levels were similar in intensity and in distribution among primary layers and most of the clones ( ). This3 
congruence of expression suggests that fast-growing clones can be taken as representative of the cell population found in primary layers.
Whereas establishing primary cultures at non-clonal density results in an initially heterogeneous population of cells with variable potential
for growth, it is likely that a subset of fast-growing cells becomes selected over time in culture and passaging, leading to a progressive
increase in culture homogeneity.
Although MSCs actively proliferate in vitro, we have shown that their proliferation potential remains within the Hayflick s limit of 50’
population doublings (PDs). About 1/3 of the clones generated at culture inception reached more than 23 25 PDs, whereas clones–
developed later (at the end of P0 and P1) showed growth arrest after 18 20 PDs ( ). The transcripts for telomerase reverse transcriptase (– 3 
) was not detected, which is in agreement with the limited, albeit large, proliferation potential.TERT 
Genostem teams have begun to unravel the network of cytokines and transcription factors controlling MSC proliferation. ( , ). Part3 4 
of this network is shown on ; it underscores the potential role of the cytokines and and of the transcription factors Fig 1 IL6 NRG1 
and .GATA6, GATA2 ZFMP2 
We have also searched for factors selecting for highly proliferative clonogenic cells. Pre-treatment of cultures with antibodies
neutralizing interferon-alpha ( ), or directed against its receptor, resulted in a marked increase in the number of very large andIFNA 
fast-growing colonies obtained in the presence of low, but necessary, concentrations of FGF-2 ( ). Blockade of the interferon-alpha4 
pathway may be a substitute for competence growth factor , with FGF-2 acting as progression growth factor . These data indicate that“ ” “ ”
inhibition of the pathway is a way to increase the recruitment of clonogenic cells with high proliferative capacity.IFNA 
Phenotype
In many publications MSCs are characterized mainly by their membrane phenotype. Studies in Genostem have shown that no single
marker was specific for bone marrow MSCs, but that a large set of markers was required to characterize this cell population. MSC
phenotype specificity has been defined by a set of 113 transcripts out of 1624 molecules coding for plasma membrane proteins inventoried
in Affymetrix microarrays ( ). This set includes 20 Clusters of Differentiation (CD), 17 of which were studied by flow cytometry at the5 
protein level and were expressed at the plasma membrane. This set allows the identification of a mesenchymal phenotype clearly distinct
from the hematopoietic/endothelial phenotypes (largely predominant in the bone marrow), and from the other skeletal mesenchymal cell
populations (periosteal cells and synovial fibroblasts) ( , ).5 6 
Another current issue was whether some of the markers characterizing human embryonic stem cells are also expressed by bone
marrow MSCs. Our studies have shown that MSCs did not express the pluripotency gene trio , and ( , ,OCT4/POU5F1 NANOG SOX2 3 4 
). The transcripts that were detected corresponded to pseudogenes ( ). Other embryonic stem cell markers were not7 OCT4/POU5F1 7 
detected, with the noticeable exception of the 2 stage-specific embryonic antigens 3 and 4 (SSEA-3, SSEA-4) resulting from the activity in
MSCs of the sialyltransferase ( ).ST3GAL3 4 
Differentiation potential
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As expected, we have shown that MSC clones differentiate into the 3 mesenchymal lineages (osteoblastic, chondrocytic and
adipocytic). We have also shown that they differentiate into the vascular smooth muscle cell lineage ( ). To induce the full differentiation,3 
cells were cultured for 21 days in the long-term culture medium described for the generation and maintenance of stromal cells associated
to hematopoiesis, since previous experiments had shown that bone marrow stromal cells followed a vascular smooth muscle differentiation
pathway ( ).8 
Previous studies performed outside Genostem ( , ) have shown that differentiation in the mesenchyme system is reversible since9 10 
apparently differentiated mesenchymal cells are able to shift their differentiation pathway under modified external conditions. This
plasticity was exemplified in clones where a switch was induced from the adipocytic to the osteoblastic lineage or from hypertrophic
chondrocytes to osteoblasts. We have shown that this concept may be extended to the vascular smooth muscle lineage since MSC clones
differentiated along this lineage can still differentiate into osteoblasts, chondrocytes and adipocytes when further cultured in osteo,
chondro or adipogenic conditions ( ).3 
Self-renewal
One of the key questions that have remained open for decades about the biology of MSCs is whether they are capable of self-renewal,
thus qualifying as bona fide stem cells rather than simply multipotent cells. Identification of the in situ counterpart of bone marrow MSCs
as CD146-expressing subendothelial (mural) cells in sinusoids has allowed to show that transplanted MSCs can reconstitute a
compartment of mural cells with phenotype and clonogenic ability identical to those of the originally explanted cells. These data, and the
possibility to secondarily passage single clonogenic CD146  progenitors, represent direct evidence in support of the ability of bone+
marrow MSCs to self-renew in vivo, and therefore of their identity as bona fide stem cells ( ).6 
Lineage priming
Lineage priming is a characteristic of stem cells whereby undifferentiated self-renewing stem cells express a subset of genes associated
to the differentiation pathways to which they can commit. Lineage priming appears to be one major attribute of the paradigmal
hematopoietic stem cell and is also suggested to be a property of embryonic stem cells. We have therefore evaluated whether lineage
priming is also an attribute of bone marrow MSCs. We have shown that fast-growing clones initiated at culture inception are primed to the
osteoblastic, chondrocytic, adipocytic and vascular smooth muscle lineages, but not to skeletal muscle, cardiac muscle, hematopoietic,
hepatocytic or neural lineages ( ).3 
Native bone marrow MSCs
Many hypotheses on the in situ original cells from which MSCs descend have been raised. Some investigators have suggested a non
mesodermal, neuroectodermal origin ( ); others have suggested that hematopoietic stem cells could generate mesenchymal cells ( ).11 12 
Our studies have shown that native bone marrow MSCs constitute a specialized, tissue-specific subset of subendothelial, mural cells
(pericytes) essential for the establishment of the hematopoietic microenvironment ( , ). Since pericytes belong to the vascular smooth6 13 
muscle cell family, these data are in agreement with the vascular smooth muscle differentiation potential of the culture-amplified cells.
Markers of bone marrow mural cells/pericytes can be used to prospectively isolate bone marrow MSCs, which can further be shown i) to
contribute to the organization of microvascular structures and of their surrogates , ii) to express a broad range of mural cellin vivo in vitro 
markers in culture, and iii) to be regulated by known regulators of microvessel assembly and maturation ( ). In addition to CD146 and6 
CD105 ( ), additional markers such as CD73, and CD200 ( ) expressed in a minor population of bone marrow mononuclear cells6 5 
(comprising 0,15 2  of the total number) can be used to isolate clonogenic bone marrow MSCs. Expression of these markers of– %
uncultured cells is retained in non-differentiated cells in culture, and then is variably modulated upon induction of differentation.
Conclusions
The data collected during the Genostem project define bone marrow MSCs as adult tissue stem cells which are : 1) deriving from a
subset of mural cells of bone marrow sinusoids, 2) self-renewing, 3) quadripotential and selectively primed to the mesenchymal and
vascular smooth muscle lineages, 4) flexible in their differentiation options (mesenchyme plasticity), and 5) able to transfer and organize
the hematopoietic microenvironment. The Genostem project has begun to unravel some of the key molecules that underly these specific
properties.
Differentiation pathways
Genetic programs for osteo and chondrogenesis are partially deciphered. In particular, the master transcription factor isRUNX2 
known to be the essential inducer of osteoblastic differentiation, and the Sox trio, and , appears to play a similar roleSOX5, SOX6 SOX9 
in chondrogenesis. However, the description of the different molecules and pathways operative in these differentiations is far from
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complete. Little is known concerning the generation of tenocytes since these cells are obtained only after implantation of thein vivo 
cultured MSCs. Genostem teams have therefore searched for novel inducers of osteo, chondrogenesis and tenogenesis that may serve as
bases for innovative therapies in regenerative medicine.
Osteogenesis
Recent advances have been made to isolate and expand MSCs from human bone marrow and to identify the mechanisms that are
responsible for the osteogenic differentiation of these cells ( ). A better understanding of the osteogenic differentiation program of MSCs14 
is however required in order to develop optimal strategies to promote osteogenesis. The Genostem program offered the possibility to study
the transcriptome of human bone marrow MSCs before and after osteoblastic differentiation. Transcription profiles were analyzed
according to published standards (PMID: 19265543) and are available via . We have then evaluated the osteogenicwww.bioretis.de 
potential of selected genes engineered in human primary MSCs in the preclinical model of long bone repair in immunodeficient mice.
Major results of these studies are reported below.
FHL2 promotes the osteogenic potential of human bone marrow MSCs
In murine and human bone marrow MSCs, we have identified , a LIM-domain protein with four-and-a-half Lim domains, as anFHL2 
early transcriptional cofactor that is upregulated at early stages of osteoblastic differentiation induced by dexamethasone. We showed that
over-expression of increased osteoblastic marker gene expression as well as osteogenesis. We further showed that silencingFHL2 in vitro 
of abolished the stimulatory effect of dexamethasone on and type I collagen. To investigate how may promoteFHL2 RUNX2 FHL2 
osteoblastic differentiation, we showed that interacts with catenin beta1 and promotes catenin beta1 nuclear translocation andFHL2 
transcriptional activity, which indicates that Wnt/catenin signaling is a critical mechanism involved in the positive effect of onFHL2 
osteoblastic differentiation in MSCs ( ). Finally, we have shown that human MSCs overexpressing produced 2 times more bone15 FHL2 
than control cells when implanted with a biomaterial in a standard ectopic subcutaneous implantation assay in immunodeficient mice
(unpublished data). Overall, these findings suggest a strategy targeted to to promote osteogenesis in human bone marrow MSCs.FHL2 
FGF-18 is an essential positive regulator of the osteoblastic differentiation program in murine bone marrow MSCs
In murine bone marrow MSCs, we have found that fibroblast growth factor 18 (FGF-18) was upregulated by dexamethasone during
osteoblastic differentiation. Overexpression of FGF-18 by lentiviral infection, or treatment of MSCs with recombinant human FGF-18
(rhFGF18), induced the expression of receptor 2 of FGF-2 ( , and downstream osteoblastic markers, and induced FGFR2) RUNX2 in vitro 
osteogenesis. Furthermore, FGF-18 appeared to promote the osteoblastic differentiation via activation of since downregulation of FGFR2 
using lentiviral shRNAs blunted the osteoblastic gene expression induced by rhFGF18. Further biochemical and pharmacologicalFGFR2 
analyses showed that rhFGF18-induced osteoblastic marker gene expression was mediated by mitogen-activated protein kinase (MAPK)
and phosphatidylinositol kinase (PI3K) signaling pathways. Thus, FGF-18 is an essential positive regulator of the osteoblastic
differentiation program in murine bone marrow MSCs. Demonstration of a similar role in human bone marrow MSCs awaits further
studies.
Activated integrin alpha 5 promotes human bone marrow MSC osteoblastic differentiation and osteogenesis in vivo
In human bone marrow MSCs, we have found that that integrin alpha5 ( ) was upregulated by dexamethasone duringITGA5 
osteoblastic differentiation. Gain-of-function studies showed that promoted the expression of osteoblastic phenotypic markers asITGA5 
well as osteogenesis; in contrast, loss-of-function studies using shRNAs showed that downregulation of endogenous in vitro ITGA5 
blunted the osteoblastic marker gene expression and the osteoblastic differentiation. Further molecular analyses showed that the enhanced
osteoblastic differentiation induced by was mediated by activation of focal adhesion kinase ( ), MAPK and PI3K signalingITGA5 FAK 
pathways. Remarkably, activation of endogenous using agonists that prime the integrin was sufficient to activate MAPK and PI3KITGA5 
signaling and to promote the osteoblastic differentiation and osteogenesis. Additionally, we demonstrated that MSCs engineered toin vitro 
overexpress exhibited a marked increase in their osteogenic potential ( ). Taken together, these findings not only revealITGA5 in vivo 16 
that is required for osteoblastic differentiation of MSCs, but also provide a novel targeted strategy using agonists toITGA5 ITGA5 
promote the osteogenic capacity of these cells. This may be used for tissue regeneration in bone disorders where the recruitment or
capacity of human bone marrow MSCs is compromised.
Conclusions
In summary, our studies led to significant advances in the mechanisms regulating bone marrow MSC osteoblastic differentiation (Fig 2
). Specifically, progress has been made in the identification of novel factors that govern and promote human bone marrow MSC
differentiation towards functional osteogenic cells. This knowledge may result in the development of innovative cell and gene therapeutic
strategies to promote bone repair.
Chondrogenesis
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The major limitations of cell therapy applications of MSC differentiated to chondrocytes are due to the lack of specific differentiation
factor and to the cell hypertrophy after implantation in vivo. Genostem has offered the opportunity to study on a large scale the factors
involved in chondrocyte biology.
One of the major results has been the identification of new transcription factors involved in early stage chondrogenic differentiation (
). Among 1354 differentially regulated genes during chondrogenesis induced from human bone marrow MSCs, 705 were up-regulated.17 
We first focused our attention on forkhead box protein O1 ( ) which was shown, using RT-PCR, to be increased by 6-fold asFOXO1A 
soon as day 2. We demonstrated that was sufficient to induce chondrogenesis. For this, we derived stable clones of the MSCFOXO1A 
murine embryonic line C3H10T1/2 over-expressing either wild-type or a constitutively active form of . After 21 days of cultureFOXO1A 
in micropellet without any differentiation factor, we could show the up-regulation of aggrecan, collagen IIB and the down-regulation of
collagen I. The engineered cells cultured in specific inducing conditions did not show higher osteogenic potential than naive cells and,
even more interestingly, showed lower adipogenic potential. After injection of the engineered cells in the intra-articular space of knee
joints, we could detect the formation of cartilage, staining positive for aggrecan and collagen II, in the areas of engineered cell injection,
thus confirming their potential to differentiate into chondrocytes.
In another work ( ), we studied the cartilaginous microenvironment generated by chondrocytes derived from human bone marrow18 
MSCs. The data obtained through large-scale Taqman Low-Density Array based on qRT-PCR have been assembled into a biological
process-oriented database that represents the first molecular profile of a cartilaginous MSC niche. It included secreted cysteine-rich
regulatory proteins (CCNs), matrix metalloproteinases (MMPs), members of the disintegrin and metalloproteinase domain-containing
protein family (ADAMs) and cell adhesion molecules (CAMs including cadherins). CCNs interact with growth factors and have important
functions in cell proliferation and differentiation. , and were upregulated after differentiation whereas and CCN3 CCN4 CCN5 CCN1 
were down-regulated. The timely degradation of the ECM is an important feature of development, morphogenesis and remodellingCCN6 
and is mainly mediated by MMPs. Only and were present in MSCs before and after differentiation, and , MMP2 MMP9 MMP7 MMP3 
and , which were not expressed in MSCs before differentiation, were highly up-regulated during chondrogenic differentiation.MMP28 
ADAMs interact with various partners such as integrins, syndecans and ECM proteins due to their role in cell-ECM interaction. , ADAM8 
, , , and were expressed in MSCs. CAMs have important functions in developmentADAM9 ADAM19 ADAM23 ADAMTS4 ADAMTS5 
and tissue morphogenesis. (N-cadherin), and were expressed in MSCs and all were decreased in chondrogenicCDH2 CDH4 CDH13 
differentiated cells. (OB-cadherin), and were up-regulated for more than 30 fold by day 21 ofCDH11 NRCAM MCAM/CD146 
chondrogenesis. Integrins act by transmitting signals from the ECM to the cellular machinery, resulting in changes in cell function. ITGA5
, , and were expressed in non differentiated MSCs with high increase of by day 21 of chondrogenicITGA7 ITGA10 ITGAE ITGA6 
differentiation.
Because chemokines and cytokines are thought to play an important role in cell activation, survival and differentiation, we analysed
the data obtained from the transcriptome study and found that and were all down-regulated after chondrogenesis.CCL2, CXCL12 FLT3L 
In contrast we observed a significant increase of and ( ).CCR1, CCR3, CCR4 CXCR4 18 
In a synthesis work on the transcriptome ( ), we were able to describe a 3-step differentiation process. The first step corresponded to19 
trancripts implicated in cell attachment and induction of apoptosis, the second step was characterized by transcripts implicated in
proliferation/differentiation, and the third step was characterized by transcripts implicated in chondrocytic differentiation and/or
hypertrophy.
In summary, our studies led to significant progress in the identification of the molecular microenvironment associated to the
chondrocytic differentiation of MSCs, and in the molecular characterization of this differentiation ( ).Fig 2 
Tenogenesis
Until the present time, therapeutic options used to repair tendon and ligament injuries have consisted in autografts, allografts or
synthetic prostheses ( ). None of these alternatives, however, has provided a successful long-term solution. In Genostem we developed20 
the hypothesis that a potent inducer of tenocytic differentiation of MSCs might result in a novel and powerful modality for tendon repair.
We have identified such an inducer in , a signaling mediator of the transforming growth factor beta/bone morphogenic proteinSmad8 
(TGF-beta/BMP) family of growth factors ( ). We characterized the role of in the tendon differentiation pathway after forced21 Smad8 
expression of the biological active form of Smad8 in the well-studied murine MSC line C3H10T  and in human bone marrow MSCs. A½
genome-wide analysis of gene expression during Smad8-dependent tenogenic differentiation has resulted in several candidate genes
potentially involved in tenogenic differentiation program. Characterization of these factors is under investigation (Nuber, H upl and Gross,ä
in preparation).
In conclusion, we have pinpointed a pathway for tendon/ligament formation ( ).Fig 2 
PRECLINICAL STUDIES IN ANIMAL MODELS
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Another large part of Genostem activity has been devoted to studies of the repair capacity of MSCs in animal models, a prerequisite
for future clinical trials. Work has been done to develop innovative biomaterials and to test the ability of MSC/biomaterial constructs to
repair bone, cartilage and tendons.
Biomaterials
The Genostem consortium enabled developing various biomaterials tailored for specific applications in bone, cartilage and tendon
repair. The biomaterials were developed and tested with bone marrow MSCs both and . The proposed biomaterialsin vitro in vivo 
followed two major research lines: biomaterials with fast translation into the clinic and innovative biomaterials with a longer path to reach
the clinical applications. Those strategies were pursued as complementary routes.
A new set of biodegradable biomaterials was developed by combining chitosan, a polysaccharide, with various biodegradable aliphatic
polyesters. Those materials were intended to combine the good biological performance of chitosan with the melt processability of the
polyesters. The materials were thoroughly characterized in terms of morphology, mechanical properties and kinetics of biodegradation
showing excellent performance compatible with the application in bone and cartilage ( ). The biological performance was evaluated in22 
vitro using the mouse bone marrow MSC line BMC9 ( , ). The combination of chitosan with poly(butylene succinate), in a equal23 24 
fraction by weight (chitosan/PBS), showed high cell viability. Porous structures were shown to support viable cultures of BMC9. This
biomaterial was compatible with the successful differentiation of BMC9 into the lineages of interest, expressing osteoblastic orin vitro 
chondrocytic genes depending on the medium used to differentiate the cells. Further work developed with primary human bone marrow
MSCs confirmed the osteoinductive capacity of the scaffolds ( ).25 
study of bone marrow MSC-scaffold combinations has been performed using non-invasive in vivo photonic imaging. DifferentIn vivo 
scaffolds (PEG-RGD, gelatine-hydrogel, calcium alginate beads) were loaded with cells expressing luciferase gene reporter and were
ectopically transplanted both subcutaneously and intramuscularly in animal models. Results have shown that intramuscular transplants
were viable for up to 90 days, thus providing a safe method for monitoring localization and viability of transplanted cells following in vivo
transplantation ( ).26 
In summary, we have developed a set of novel scaffolds and procedures that will be useful for the repair of both bone and cartilage in
the presence of MSCs.
Bone repair
For evaluation of the osteogenic functionality of MSCs, cell-scaffold constructs were transplanted in femoral bone defects inin vivo 
immunodeficient mice. Cells were isolated and expanded according to the Genostem protocol. Following osteogenic differentiation, cells
were loaded onto fibrin/ceramic constructs and transplanted in athymic nude mice. After eight weeks tissue samples were processed for
histology and immunohistochemistry. Previous results have shown that subcutaneous transplants of cell/ceramic constructs resulted in
ectopic bone formation ( ). When the same cell-scaffold constructs were implanted in femoral critical size defect we observed, 8 weeks27 
after transplantation, bone formation in place of fibrous tissue, as shown in (Srouji et al. preliminary results).Fig 3A and 3B 
Cartilage repair
Clinical application of MSC-differentiated chondrocytes in rheumatic disease like osteoarthrirtis (OA) requires appropriate scaffolds
that are chondro-inductive, bio-resorbable and non inflammatory, and are adapted for intra-articular injection. Genostem offered the
opportunity to test different scaffolds combined with human bone marrow MSCs.in vivo 
In order to deliver the growth factor TGF-beta3 (TGFb3) in a controlled manner we developed microparticles with a bio-mimetic
surface of matrix molecules (Pharmacologically Active Microcarriers or PAM). We selected a combination of fibronectin (FN) and
poly-D-lysine as the best bio-mimetic surface. The cell adhesion protocol has been completed by an overnight cell culture step necessary
to obtain the formation of PAM and cell aggregates. When MSCs were cultured in presence of PAM-TGFb3, cells rapidly adhered onto
the PAMs and progressively aggregated to form a unique pellet-like structure from day 7 to day 21. In PAM-TGFb3-induced aggregates,
high expression of chondrogenic markers occurred in a time-dependent manner whereas expression of osteogenic and adipogenic markers
was lower than those observed when PAM-FN were used. Intra-articular injection of MSCs mixed with PAM-TGFb3 confirmed their
capacity to form a neotissue with characteristics of cartilage.
We used the ovine model of cartilage repair to demonstrate the capacity of bone marrow MSCs combined with fibrin clot ±
chitosan/PBS scaffolds and TGFb3 to induce cartilage tissue in a preclinical model ( ). Ovine MSCs were shown to display the three28 
main characteristics of MSCs: adherence to plastic, characteristic phenotypic profile (positive for CD44, CD105 and vimentin, and
negative for CD34 and CD45) and trilineage differentiation potential. Ovine MSCs, either in fibrin clot alone or with chitosan  TGF 3,± β
were able to repair a partial-thickness defect in the cartilaginous tissue of sheep patella ( ).Fig 3C and 3D 
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Tendon repair
The strategies for MSC-mediated tendon repair was based on the Smad8-dependent tenogenic differentiation model described above.
Tissue regeneration of a rat achilles tendon partial-defect model, using C3H10T  MSCs expressing Smad8 and BMP-2 was demonstrated½
( ). We observed the formation of fibrous ligament-to-bone and tendon-to-bone interfaces ( entheses  or osteotendinous junctions) after21 “ ”
heterotopic implantation of the genetically engineered MSC line in muscle tissue as shown of . Entheses serve to dissipate stressFig 3E 
between soft tissue and bone and surgical reconstruction of these interfaces is an issue of considerable importance. Entheses are prone to
injury and the integration of bone and tendon/ligament is in general not satisfactory. Our findings should eventually contribute to the
establishment of MSC-dependent regenerative therapies for tendon-bone insertions (Shahab-Osterloh, , under revision).et al 
Moreover, a novel method was devised to quantify tendon biomechanics by minimally invasive procedures establishingin vivo 
endoscopic fibered confocal fluorescence microscope images of externally loaded tendons. Through a series of image post-processing
steps, cellular displacements may be reduced to tissue strains, giving a quantifiable estimate of the functional integrity of the tendon tissues
( ). These methods may enable to assess the impact on normal tendon homeostasis and healing processes by minimally invasive29 –31 
procedures.
CONCLUSIONS AND PERSPECTIVES
Concerning bone marrow MSC biology, work performed in Genostem has has helped solve three major problems. We now know 1)
where the native cells are located (on the abluminal side of endothelial cells of sinuses) and how to select them, 2) that stromal cells
forming the niche of hematopoietic stem cells and bone marrow MSCs are the same entity, thus resolving a long-standing issue, and 3) that
clonal highly proliferative culture-amplified cells are bona fide stem cells since sharing with the other paradigmal adult stem cells, the
hematopoietic stem cells, two major properties, that of self-renewal and that of multipotential priming. Many issues remain to be solved.
Are MSCs also primed to the tenogenic lineage ? Is it possible to describe for the MSC system a hierarchy among precursors that would
discriminate between self-renewing multipotential MSCs and progenitors/transit amplifying cells devoid of self-renewal capacity, and
more restricted in their differentiation ability (note that such classical  model for stem cell differentiation in other systems is presently” ”
under much debate ( , )) ? Is the self-renewal capacity of MSCs comparable to that of hematopoietic stem cells (sequential32 33 
transplantations would solve this problem) ? Would cross-inhibitory loops between transcription factors account for multipotential lineage
priming in MSCs, as suggested for hematopoietic or embryonic stem cell lineage priming ( ) ? Does the reprogrammation of MSCs into34 
non primed lineages ( , ) implies reversion to pluripotent cell stage as described for skin fibroblasts ( ), or is true35 36 37 
transdifferentiation possible ( )? What is the influence of the surrounding matrix and biomechanical stress on lineage priming and38 
programming/reprogramming of MSCs ( ) ?39 
Genostem identified and developed a set of new biomaterials and scaffolds that showed adequate performance in vivo for the repair of
bone and cartilage. The cohort of biomaterials and scaffolds proposed by Genostem continues being developed towards pre-clinical testing
for the repair of connective tissues aiming at reaching the clinical testing stage.
Concerning bone repair, work performed in Genostem led to identify novel genes and factors that promote MSC osteogenic
differentiation and osteogenesis in vitro and in vivo. Future studies, now ongoing, will determine whether some of these genes or factors
can be used to promote bone repair in preclinical settings. Ongoing studies are also aimed at identifying other genes and proteins that are
upregulated during MSC osteogenic differentiation and can be used to promote the osteogenic and bone repair processes.
Concerning cartilage repair, work performed in Genostem opens perspectives for the cell therapy of disorders including cartilage
defect and cartilage damage related to arthritis/osteoarthitis. However, results in the long term evaluating integration of the newly formed
tissue with the native cartilage need to be obtained before large application in clinical practice can be envisioned.
Concerning tendon repair, identification of the signalling molecules implicated in tenogenesis has been a major step forward. Future
studies will determine how this newly-acquired knowledge may be applied to preclinical models using human bone marrow MSCs, before
considering clinical application in cases of tendon rupture.
Whatever the site of repair, the mechanisms of repair still need to be elucidated. A traditional view would be that the transplanted
donor MSCs migrate to the injured site where they proliferate and differentiate into appropriate cells (osteoblasts, chondrocytes or
tenocytes pending on the injured tissue). An alternative view would be that MSCs provide growth factors helping in situ host MSCs to
proliferate and differentiate. Such trophic effect has been recently shown in an animal model of fracture healing ( ) and is suggested to40 
be the major mechanism to explain the beneficial role of MSC administration in non-orthopedic-related disorders such as vascular repair (
).41 
A last important issue is whether bone marrow MSCs are identical to other connective-tissue forming cells not found in bone marrow
(adipose tissue, umbilical cord vessel, Wharton s jelly, placenta ). Many authors suggest this to be the case, the major arguments being’ …
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the similarity of phenotype and of differentiation capacity (into osteoblasts, chondrocytes, adipocytes and even myocytes) between cells
derived from bone marrow and other tissues ( ). Data from Genostem contradict this hypothesis stressing that bone marrow MSCs42 
present unique properties : specific expression of certain membrane antigens, unique ability to form bone and transfer the hematopoietic
microenvironment in vivo after transplantation to ectopic sites, specific transcriptomic profile  ( , ). Further studies should more… 5 –7 43 
closely discriminate the connective-tissue stem cell types with regard to their tissue of origin.
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Figure 1
Gene network controlling bone marrow MSC proliferation
We selected 64 transcripts that were downregulated after adipocytic, osteoblastic and chondrocytic differentiation ( ). Ingenuity software3 
allowed to determine the network with the highest score (score of 46, including 21 focus molecules effectively detected in the MSCs out of 30
molecules belonging to the theoretical network). Focus molecules are indicated by filled symbols.
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Fig 2
Major lineage-determining effectors in MSCs
Lineages are regulated to a considerable extent by members of the TGF-  superfamily of growth factors activating downstream Smadβ
signaling mediators. This is a modified diagram from ( ). 44 Abbreviations: BMP: bone morphogenetic protein; C/EBP: CCAAT/enhancer
binding protein; GDF: growth and differentiation factor; MRTF: myocardin-related transcription factor; Osx: Osterix; PPAR : peroxisome
proliferator-activated receptor- ; Runx2: Runt-related transcription factor 2; Sox5/6/9: SRY (sex determining region Y)-box 5, -box 6, -box 9;
SRF: serum response factor; TGF- : Transforming growth factor- .β β
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Fig 3
Connective tissue repair by MSCs
A, B: Orthotopic bone repair Segmental critical size bone defect (2 mm) created in femoral midshaft of athymic nude mice; the defect was
filled with MSC-ceramic transplant. : Defect in the absence of grafting; note the presence of fibrous tissue filling the gap A : BoneB 
reconstruction (8 weeks after engraftment) was apparent in place of the fibrous tissue (arrow). C, D: Orthotopic cartilage repair Large size
defect was created in the patella of Merinos sheep. Autologous bone marrow MSCs were harvested and expanded in culture for 2 passages,
before being seeded in fibrin clots or scaffolds of chitosan  TGFb3. The material was implanted in the patella defect. Animals were left in the+
field for 8 weeks before sacrifice. : lesions filled with ovine MSC in fibrin clot C : Lesions filled with ovine MSCs embedded in chitosanD 
scaffolds  TGF 3. Arrows indicate the junction between endogenous and new tissues + β E: Heterotopic tendon formation The intramuscular
transplantation of adenovirally modified MSCs (C3H10T  embryonic cell line) expressing and leads, 4 weeks after½ Smad8 Bmp2 
implantation, to the heterotopic formation of tendinous elements (hematoxylin and eosin staining). The tendinous element (shown within the
black and white arrowheads) is characterized by a tendon-typical crimp pattern and flattened tenocyte-like cells. Abbreviations: B, bone; M,
muscle; T, tendon
